(NASDAQ: ILMN) Illumina's forecast annual revenue growth rate of 19.47% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 72.18%.
Illumina's revenue in 2023 is $4,699,000,000.On average, 6 Wall Street analysts forecast ILMN's revenue for 2023 to be $883,062,694,800, with the lowest ILMN revenue forecast at $836,505,670,000, and the highest ILMN revenue forecast at $956,352,540,000.
In 2024, ILMN is forecast to generate $1,035,958,609,400 in revenue, with the lowest revenue forecast at $963,147,900,000 and the highest revenue forecast at $1,145,408,264,000.